PerpEquities

Medline Inc. (MDLN) cash flow statement

NASDAQ · Healthcare · Medical - Instruments & Supplies · 45,000 employees · CEO James Boyle

Price
$37.55 0.0%
Market cap
$32.5B
Enterprise value
$42.8B Data as of 2026-11-22
Last report
Q3 '26 filed 2026-11-04
Next report
2027-02-24 EPS est. $0.39

In Q3 '26 Medline Inc. (MDLN) generated $1.03B of operating cash flow, invested $141M in capital expenditure and kept $884M of free cash flow. Over the last four quarters free cash flow was $1.9B.

Cash flow

Cash flowTrendQ3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating
Net income$324M$322M$333M$322M$182M$129M$139M$428M
Depreciation & amortization$248M$247M$250M$253M$261M$254M$256M$259M
Stock-based compensation$0$0$0$0$0$0$29M$52M
Deferred income tax$0$0$0$0$0$37M$64M$39M
Change in working capital$62M$5M-$507M$1M-$282M-$161M-$163M$429M
Other non-cash items$88M$108M$121M$60M$68M$153M$390M-$182M
Operating cash flow$722M$682M$197M$636M$229M$412M$715M$1.03B
Investing
Capital expenditure-$107M-$98M-$110M-$101M-$138M-$96M-$111M-$141M
Acquisitions-$890M$6M$0$0$0$0$0$0
Purchases of investments$0$0$0$0$0$0$0-$1.27B
Other investing-$1M$0-$33M$0$0$0-$350M$435M
Investing cash flow-$998M-$92M-$143M-$101M-$138M-$96M-$461M-$980M
Financing
Net debt issued / repaid-$513M$0-$19M-$24M-$4.05B$0-$38M-$7M
Share buybacks-$3M-$9M-$6M-$18M-$1.97B$0$0$0
Dividends$0$0-$303M-$119M-$96M$0$0$0
Other financing (incl. tax on vested shares)-$42M$0$0$0-$36M-$10M-$121M-$50M
Financing cash flow-$558M-$9M-$328M-$161M$897M-$13M-$159M-$48M
Summary
FX effect on cash$834M$9M$18M-$3M-$1M-$7M-$4M-$3M
Net change in cash$0$590M-$256M$371M$987M$296M$91M-$6M
Free cash flow (OCF - capex)$615M$584M$87M$535M$91M$316M$604M$884M
Income taxes paid$0$0$0$0$0$0$0$31M
Interest paid$0$0$0$0$0$0$263M$38M

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-26, 10-Q 2026-06-27, 10-Q 2026-03-28, 10-K 2025-12-31

Data as of 2026-11-22